S-1/A: Carlsmed Files for IPO, Eyes 2026 Cervical Spine Market Expansion Amid Strong Revenue Growth

Sentiment:

Initial Public Offering Registration Statement Amendment 15 July 2025 10:39 AM

Carlsmed, a medical technology company specializing in AI-enabled personalized spine surgery, is pursuing an initial public offering of 6.7 million shares, aiming to raise approximately $88.3 million to fuel commercialization and R&D, particularly for its planned 2026 cervical spine fusion market entry.

Capital raiseThe company is undertaking an Initial Public Offering (IPO) of 6,700,000 shares of common stock.The expected initial public offering price is between $14.00 and $16.00 per share.The estimated net proceeds to the company from this offering are approximately $88.3 million (or $103.3 million if underwriters exercise their option in full), assuming a $15.00 per share midpoint price.Proceeds are intended to support commercialization of the aprevo Technology Platform ($24.7 million for sales and marketing), fund research and development ($45.9 million for R&D, including cervical spine fusion development), and for working capital and general corporate purposes.Entities affiliated with B Capital Group and U.S. Venture Partners have indicated interest in purchasing up to approximately $20 million and $11 million, respectively, in shares in this offering, though these indications are not binding.

Summary

Carlsmed is a commercial-stage medical technology company focused on AI-enabled personalized spine surgery solutions, aiming to become the standard of care for spine fusion.
The aprevo Technology Platform includes AI-enabled software, custom-designed interbody implants, and single-use surgical instruments, currently marketed for lumbar spine fusion.
The company is developing the aprevo Technology Platform for cervical spine fusion surgeries, with commercialization expected in 2026, following FDA 510(k) clearance in November 2024 and a successful first in-human personalized cervical procedure in July 2025.
CMS announced proposed X-codes in April 2025 for custom-made anatomically designed fusion devices for cervical spine fusion, potentially offering NTAP of up to $21,125 per procedure if approved.
The estimated total addressable market for the aprevo Technology Platform in the United States is approximately $13.4 billion for lumbar fusion procedures, based on 445,200 expected surgeries in 2025 and current average selling price.
As of March 31, 2025, 177 surgeon users had completed one or more procedures using the aprevo Technology Platform, up from 103 as of March 31, 2024, and 199 as of June 30, 2025, compared to 116 as of June 30, 2024.
Revenue for the three months ended March 31, 2025, was $10.2 million, a 100.3% increase from $5.1 million in the same period of 2024.
Full-year revenue for 2024 was $27.2 million, a 97.2% increase from $13.8 million in 2023.
Gross margin for the three months ended March 31, 2025, was 74.9%, up from 72.0% in the prior year period.
Net loss for the three months ended March 31, 2025, was $5.7 million, compared to $5.4 million for the same period in 2024.
Full-year net loss for 2024 was $24.3 million, compared to $18.9 million in 2023.
As of March 31, 2025, the company had an accumulated deficit of $76.9 million.
The company's patent portfolio includes 38 issued patents and approximately 120 pending patent applications as of June 30, 2025, covering implants, manufacturing, design, software, and AI algorithms.
Approximately four million radiographic images have been used to train AI models, and over one million images of patients using the aprevo Technology Platform have been analyzed as of March 31, 2025.

Sentiment

Score: 7

Explanation: The company demonstrates strong revenue growth and significant innovation in a large addressable market, supported by positive clinical data and favorable reimbursement. However, it is still operating at a net loss with increasing expenses, and faces substantial risks related to competition, regulatory compliance, and reliance on third-party manufacturers. The IPO is a critical step to fund continued growth and R&D, but profitability remains a future goal.

Positives

Experienced significant sequential quarterly and annual revenue growth, with 100.3% period-over-period growth for Q1 2025 ($10.2M vs. $5.1M) and 97.2% year-over-year growth for 2024 ($27.2M vs. $13.8M).
Gross margin improved to 74.9% for Q1 2025 from 72.0% in Q1 2024, and to 73.8% for 2024 from 71.9% in 2023, indicating strong unit economics.
Successfully completed the first in-human personalized cervical procedure in the United States using the aprevo Technology Platform in July 2025.
Received FDA 510(k) clearance for aprevo interbody implants for cervical interbody fusion surgeries in November 2024, after previously receiving FDA Breakthrough Device Designation.
CMS announced proposed ICD-10-PCS (X-codes) in April 2025 for custom-made anatomically designed fusion devices for cervical spine fusion, potentially offering NTAP of up to $21,125 per procedure.
Established new MS-DRG codes in October 2024 for lumbar fusions utilizing custom-made anatomically designed interbody fusion devices, providing premium reimbursement rates to hospitals.
Clinical studies and real-world evidence support the aprevo Technology Platform's benefits, including improved post-operative alignment and reduced revision surgery rates.
Interim data from the COMPASS Registry for ASD patients showed a 1.5% revision rate attributable to mechanical complications, significantly lower than published rates for traditional spine fusions (14% to 32%).
Operates an asset-light business model with on-demand, patient-specific implant manufacturing, allowing for limited capital investment in inventory.
Streamlined digital production system (DPS) enables delivery of sterile, patient-specific implants within 10 business days of surgical plan approval.
Strong competitive position supported by a robust intellectual property portfolio (38 issued patents, ~120 pending applications as of June 30, 2025) and a comprehensive data moat (4M radiographic images for AI training, 1M+ analyzed, 40,000+ digital twin 3D models).
Experienced leadership team with deep expertise across relevant disciplines.

Negatives

Continues to incur net losses, with $5.7 million in Q1 2025 and $24.3 million in 2024, and an accumulated deficit of $76.9 million as of March 31, 2025.
Operating expenses increased significantly, with Q1 2025 operating expenses at $13.355 million (131.1% of revenue) compared to $8.993 million (176.8% of revenue) in Q1 2024.
Gross margin for Q2 2025 is expected to slightly decrease (72.5%-73.5%) compared to Q2 2024 (75.0%) due to increased expedite fees from CMOs to meet demand.
Reliance on a limited number of contract manufacturing organizations (CMOs) for all manufacturing processes, increasing risk of supply delays or insufficient quantities.
Current CMOs are not under long-term contracts, posing a risk of termination or price increases.
Significant increase in research and development expenses ($14.3M in 2024 vs. $7.4M in 2023) and sales and marketing expenses ($21.5M in 2024 vs. $15.1M in 2023) contributes to ongoing losses.
Preliminary Q2 2025 financial results are unaudited estimates and subject to change, cautioning against undue reliance.
The company's ability to use net operating loss carryforwards may be limited due to certain tax law provisions (Sections 382 and 383 of the Code).

Risks

Dependence entirely on sales of aprevo interbody implants for revenue; failure to achieve substantial market acceptance and adoption would harm the business.
Limited operating history and periods of significant business changes make it difficult to evaluate future prospects and manage business fluctuations effectively.
Inability to successfully launch the aprevo Technology Platform for cervical spine fusion surgeries would limit future growth.
Managing the on-demand, customized implant model is expensive, time-consuming, and subject to uncertainties; inability to consistently meet demand on a timely basis could lead surgeons to competitors.
Reliance on a limited number of CMOs increases risk of insufficient quantities, unacceptable costs, and reduced control over manufacturing, potentially delaying or impairing commercialization.
If third parties assisting with premarket development activities for future products do not perform as required, regulatory clearance or commercialization may be delayed or prevented.
Operating in a highly competitive industry; competitive pressures or new developments by competitors could render the aprevo Technology Platform non-competitive or obsolete.
Future sales in international markets will subject the company to additional costs and risks, including regulatory hurdles and market acceptance challenges.
Failure to attract and retain senior management and other key personnel, especially in AI and machine learning, could materially adversely affect the business.
Reliance on independent sales agents to generate revenue subjects the company to risks if relationships are impaired or terminated, or if agents fail to comply with regulations.
Inability to successfully develop new products or effectively manage their introduction or improvement could adversely affect the business.
Exposure to product and other liability claims, which could require substantial payments, divert management attention, and harm reputation.
Off-label use of aprevo interbody implants may harm reputation or result in fines/sanctions if deemed promotional.
Recalls of products, voluntary or mandated, or discovery of serious safety issues could significantly impact the company.
Unforeseen adverse events or undesirable side effects with products could require market withdrawal or safety warnings.
The estimated total addressable market may be smaller than projected, impacting revenue potential.
Discovery of alternative technologies or other personalized spinal implant technologies could decrease demand for products.
Quarterly and annual results may fluctuate significantly due to various factors, including market acceptance, reimbursement changes, and economic conditions.
Macroeconomic conditions (inflation, interest rates, geopolitical instability) could adversely affect demand and increase costs.
Uncertainty regarding third-party payor coverage and adequate reimbursement levels; failure to obtain/maintain these could limit marketability and revenue.
Non-compliance with federal and state fraud and abuse laws and transparency laws could lead to substantial penalties.
Employees, independent sales agents, and consultants may engage in misconduct or improper activities, leading to regulatory non-compliance.
Claims of wrongful use or disclosure of trade secrets or breach of non-competition agreements could lead to damages or litigation.
Healthcare policy changes, including reforms to the U.S. healthcare system, could adversely affect profitability.
Extensive government regulation and oversight; failure to comply could harm the business.
Failure to maintain marketing authorizations or timely obtain necessary authorizations for future products could have a material adverse effect.
Risks related to obtaining necessary foreign marketing authorizations for international expansion.
Failure to comply with the Foreign Corrupt Practices Act (FCPA), economic and trade sanctions, and similar laws could lead to penalties.
Actual or perceived failures to comply with data privacy and security laws could adversely affect the business.
Risks associated with the use and development of AI models, including incorrect design, biased data, or unforeseen defects.
Information technology system failures, cyberattacks, or cybersecurity deficiencies could disrupt operations and lead to liabilities.
Inability to obtain, maintain, enforce, and protect intellectual property rights could harm competitive position.
Challenges in enforcing intellectual property rights globally, especially in countries with weaker protections.
Claims challenging inventorship or ownership of patents and other intellectual property rights.
Dependence on licensed intellectual property rights; inability to license or acquire necessary rights could harm the business.
Products contain third-party open-source software components; non-compliance with licenses could restrict sales or lead to litigation.
Cash deposits with financial institutions exceed insured limits, posing risk in case of bank failure.
Subject to legal and arbitration proceedings that may prevent business activities or incur additional costs.
Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Insurance may not cover all potential losses or liabilities.

Future Outlook

The company expects to commercialize the aprevo Technology Platform for cervical fusion surgery in 2026, assuming necessary additional FDA clearances are obtained. It plans to continue building its cervical software platform and personalized plating solutions in 2025. The company also intends to pursue international markets and develop the platform for additional indications and musculoskeletal applications beyond the spine. Operating expenses are expected to increase significantly in the coming years due to expansion, R&D, and public company costs, with a goal for these costs to decrease as a percentage of revenue over time. Gross margin is expected to remain relatively constant in the short term and modestly increase over the medium and long term with economies of production scale and increased leverage of AI technologies.

Management Comments

"We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond."
"We are focused on becoming the standard of care for spine fusion surgery."
"We believe that these limitations and poor clinical outcomes not only impair patients health and quality of life but also impose a significant economic burden on the healthcare system with the direct and indirect costs of a revision surgery frequently exceeding $100,000."
"We believe this also helps drive surgeon adoption while also supporting patient access to our patient-centric technology."
"We believe this suggests ample opportunity to grow our surgeon user base and further penetrate the market by capturing more surgeons across the United States."
"We believe that the continued growth of our company will be driven by the following success factors: Paradigm-shifting, patient-centric platform aiming to set the new standard of care for spine surgery; Large and established addressable market opportunity with a significant unmet clinical need; Compelling benefits for patients and providers supported by a robust body of clinical studies and real-world evidence; Established and distinct hospital reimbursement with favorable payment levels; Scalable, inventory-light business model with attractive gross margins; Strong competitive position supported by robust intellectual property and comprehensive data moat; Experienced leadership team."
"We expect these expedite fees to decrease over time as we seek to improve operational processes and procedural workflows utilized by surgeons."
"We expect that our cost of sales will continue to increase in proportion to recognized revenue."
"We expect our gross margin to remain relatively constant over the short term and to modestly increase over the medium and long term with economies of production scale, increased leverage of our AI Technologies, and other manufacturing efficiencies."
"We expect our research and development expenses to increase as we continue to accelerate product and software innovation, develop additional clinical data, and expand our manufacturing capabilities."
"While we expect sales and marketing expenses to continue to increase in absolute value, we expect that these costs will decrease as a percentage of revenue over time."
"While we expect general and administrative expenses to continue to increase in absolute value, we expect that these costs will decrease as a percentage of revenue over time."
"We believe that our existing cash on hand will be sufficient to meet anticipated capital requirements for its operations for at least 12 months from the date of the issuance of the accompanying financial statements."

Industry Context

Carlsmed operates in the highly competitive medical device industry, specifically targeting the spine fusion market, which is characterized by rapid technological change. The company aims to disrupt the traditional spine fusion market, which relies on 2D imaging and stock implants, by offering an AI-enabled personalized solution. Traditional methods are noted to have limitations leading to poor outcomes and high revision rates (14-32% for mechanical complications in ASD patients). Carlsmed's approach addresses these shortcomings with 3D planning, patient-specific implants, and post-operative data insights. The market for lumbar fusion is estimated at $13.4 billion in the U.S. for 2025, with an additional opportunity in cervical fusion (372,600 procedures expected in 2025). The company's strategy aligns with broader healthcare trends emphasizing personalized medicine, improved patient outcomes, and cost reduction.

Comparison to Industry Standards

Traditional spine fusion surgery often lacks robust pre-operative planning, relying on 2D imaging, unlike aprevo's AI-enabled 3D planning and visualization software.
Stock implants used in traditional surgery are largely symmetric and fixed in size, often failing to match unique patient anatomy, whereas aprevo offers custom-made, anatomically designed interbody fusion devices.
Traditional spine fusion can lead to revision rates for mechanical complications between 14% and 32% over one to two years in ASD patients (Kent et al., 2024), while aprevo's COMPASS Registry interim data showed a 1.5% revision rate for mechanical complications in ASD patients at one-year follow-up.
A study of 997 patients treated with stock implants showed a revision rate for mechanical complications following spinal deformity surgery of 8.7% by one-year follow-up and 14.4% by two-year follow-up (Lafage et al., 2024), significantly higher than aprevo's observed rates.
Traditional methods often involve prolonged trialing processes in the OR with dozens of stock implant options, increasing surgery time and radiation exposure, which aprevo's patient-specific implants eliminate.
Post-operatively, traditional spine fusion lacks integrated means for reconciling achieved outcomes against surgical objectives, unlike aprevo intelligence which provides detailed analytics and refines algorithms.
The company's on-demand, made-to-order inventory model for patient-specific implants contrasts with traditional manufacturers who must hold large amounts of stock inventory.
MS-DRG codes for aprevo procedures provide premium reimbursement to hospitals (incremental $12,000 to $50,000 for lumbar fusions) relative to those using stock implants, indicating a favorable reimbursement landscape compared to standard offerings.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Commercial Officer	NA	William (Scott) Durall	December 2024	Promotion from Senior Vice President, Marketing.
Chief Financial Officer and Treasurer	NA	Leonard (Leo) Greenstein	August 2023	Appointment to role.
Chief Intellectual Property Officer	NA	Niall Casey	December 2023	Transition from Chief Technology Officer.
Director	NA	Kevin OBoyle	September 2024	Appointment to Board of Directors.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Classification	Board of Directors will be divided into three staggered classes with three-year terms, with one class elected each year.	Immediately prior to IPO completion	May delay or prevent stockholder efforts to effect a change of management or control, potentially leading to entrenchment.
Director Removal Standard	Directors may only be removed for cause by holders of at least 66 2/3% of voting power, subject to preferred stock rights.	Immediately prior to IPO completion	Increases difficulty for stockholders to remove directors, enhancing board stability but potentially hindering accountability.
Director Vacancy Filling	Vacancies, including newly created directorships, may be filled by affirmative vote of a majority of directors then in office, even if less than a quorum.	Immediately prior to IPO completion	Allows the existing board to maintain control over its composition, potentially limiting stockholder influence.
Stockholder Action Requirement	Any action by stockholders must be effected at a duly called annual or special meeting, not by written consent or electronic transmission.	Immediately prior to IPO completion	Restricts stockholders' ability to act quickly without a formal meeting, potentially delaying activist efforts.
Special Meeting Call Authority	Special meetings of stockholders may only be called by the Board of Directors (majority vote), not by stockholders.	Immediately prior to IPO completion	Limits stockholders' ability to call special meetings to address urgent matters or propose changes.
Cumulative Voting Rights	Does not provide for cumulative voting rights, allowing majority holders to elect all directors, unless subject to California Corporations Code Section 2115(b).	Immediately prior to IPO completion	Reduces the ability of minority stockholders to elect board representatives.
Preferred Stock Issuance Authority	Board of Directors has authority to issue up to 10,000,000 shares of preferred stock in one or more series with designated rights, preferences, and privileges, without further stockholder action.	Immediately prior to IPO completion	Provides flexibility for future financing and acquisitions but could be used to create anti-takeover defenses or dilute common stockholders' voting power.
Code of Business Conduct and Ethics	Board of Directors adopted a Code of Business Conduct and Ethics applicable to all employees, officers, agents, and representatives.	Upon effectiveness of registration statement	Establishes ethical guidelines and compliance standards for public company operations.
Audit Committee Composition	Audit committee will consist of Kevin OBoyle (Chair), Kevin Sidow, and Phil Young, all determined to be independent.	Upon effectiveness of registration statement	Ensures compliance with Nasdaq and SEC independence requirements for financial oversight.
Compensation Committee Composition	Compensation committee will consist of Kevin Sidow (Chair), Kevin OBoyle, and Robert Mittendorff, all determined to be independent.	Upon effectiveness of registration statement	Ensures compliance with Nasdaq and SEC independence requirements for executive compensation oversight.
Nominating and Corporate Governance Committee Composition	Nominating and corporate governance committee will consist of Jon Root (Chair), Robert Mittendorff, and Kevin Sidow, all determined to be independent.	Upon effectiveness of registration statement	Ensures compliance with Nasdaq independence requirements for board nominations and governance practices.
Lead Independent Director	Kevin Sidow will be appointed as lead independent director.	Upon effectiveness of registration statement	Provides independent leadership for the Board, especially given the Chairman is not independent.
Indemnification Agreements	Will enter into indemnification agreements with executive officers and directors, providing contractual rights to indemnification and expense advancement to the fullest extent permitted by Delaware law.	Prior to IPO closing	Necessary to attract and retain qualified personnel but may reduce available funds to satisfy third-party claims.
Exclusive Forum Provision	Delaware Court of Chancery is the exclusive forum for certain corporate disputes, and federal district courts for Securities Act claims.	Immediately prior to IPO completion	Aims for consistent application of law and efficient case administration but may limit stockholders' ability to choose a favorable judicial forum.
Related Person Transactions Policy	Board intends to adopt a written policy for review and approval/ratification of related person transactions by the audit committee, in conformity with Nasdaq requirements.	Upon IPO consummation	Mitigates conflicts of interest and ensures proper valuation in related party dealings.

Legal Proceedings

Not presently a party to any litigation the outcome of which, if determined adversely, would materially and adversely affect the company's business, financial condition, or results of operations.
Future litigation may be necessary to defend intellectual property rights or other matters, which could be costly and burdensome.

Related Party Transactions

In March, September 2024, and January 2025, issued 6,007,866 shares of Series C convertible preferred stock for $64.5 million, with significant purchases by entities affiliated with B Capital Group ($44.0 million) and U.S. Venture Partners ($18.0 million). Robert Mittendorff (director) is affiliated with B Capital Group, and Jon Root (director) and Philip Young (director) are affiliated with U.S. Venture Partners.
In April 2022, issued 4,335,051 shares of Series B convertible preferred stock for $30.0 million, with significant purchases by entities affiliated with B Capital Group ($20.0 million) and U.S. Venture Partners ($6.0 million). Michael Cordonnier (CEO, Chairman), Niall Casey (Chief IP Officer, Director), Kevin Sidow (director), and Philip Young (director) also purchased Series B shares.
Party to an amended and restated investor rights agreement with certain holders of convertible preferred stock and common stock, including affiliated entities of executive officers and directors, granting registration rights.
Party to an amended and restated voting agreement with certain holders of convertible preferred stock and common stock, including affiliated entities of executive officers and directors, which will terminate upon IPO completion.
Party to an amended and restated right of first refusal and co-sale agreement with certain holders of convertible preferred stock and common stock, including affiliated entities of executive officers and directors, which will terminate upon IPO completion.
Entered into new employment agreements in June 2025 with Michael Cordonnier, Leonard Greenstein, and William Durall, providing for base salary, target bonus, and severance benefits.
Granted Michael Cordonnier 112,478 performance and market-based vesting RSUs in March 2025.
Granted Kevin OBoyle an option to purchase 103,702 shares in November 2024 and Kevin Sidow an option to purchase 44,802 shares in May 2024 for their board service.
Will enter into indemnification agreements with executive officers and directors prior to IPO closing.

Stakeholder Impact

**Shareholders**: Potential for dilution from the IPO and future equity issuances. Existing shareholders will experience immediate and substantial dilution. Future stock price volatility is expected. Significant control by principal stockholders and management (57.1% post-IPO) may limit influence of new public shareholders.
**Patients**: The aprevo Technology Platform aims to improve outcomes and reduce the need for revision surgeries for spine fusion patients, potentially enhancing quality of life and reducing chronic pain and disability.
**Surgeons**: The platform provides personalized surgical plans and implants, aiming to improve alignment predictability and simplify intra-operative workflow by eliminating the need for trial-and-error with stock implants. Continued training and medical education programs are planned.
**Hospitals**: The aprevo Technology Platform offers premium reimbursement rates for lumbar fusion procedures and potential NTAP for cervical procedures, which could increase hospital revenue. The on-demand, sterile, single-use instrument model eliminates additional processing expenses and reduces inventory management burden for hospitals.
**Employees**: The company is expanding its sales, marketing, and R&D teams, creating new employment opportunities. Equity incentive plans are in place to attract, retain, and motivate personnel. However, rapid growth places significant demands on management and resources.
**Suppliers/CMOs**: The company relies heavily on a limited number of CMOs for manufacturing, creating a critical dependency. Increased demand could strain CMO capacity and lead to expedite fees, impacting costs.
**Creditors**: The company has outstanding indebtedness under the Customers Loan Agreement, with covenants that limit financial flexibility. The IPO proceeds will improve liquidity and reduce reliance on debt for growth in the short term.

Next Steps

Complete the initial public offering and list common stock on The Nasdaq Global Select Market under the symbol CARL.
Continue to drive adoption and market share capture for aprevo in lumbar fusion surgeries.
Launch the aprevo Technology Platform for cervical spine fusion surgeries, expected in 2026, assuming necessary additional FDA clearances.
Pursue additional FDA clearances for advancements to the cervical software platform and personalized plating solutions in 2025.
Invest in further growing the base of clinical evidence, including the ongoing COMPASS Registry (final data anticipated early 2027).
Continue to develop research and development initiatives, including predictive analytic models and expansion into additional spinal indications (e.g., cervical corpectomy, cervical disc arthroplasty) and other musculoskeletal applications.
Engage in market access initiatives for strategic international regions.
Improve operational processes and procedural workflows to reduce expedite fees from CMOs over time.
Comply with public company reporting requirements and Sarbanes-Oxley Act provisions.

Key Dates

Date	Description
2018-06-01	Carlsmed, Inc. incorporated in Delaware.
2019-09-17	Carlsmed, Inc. Stock Incentive Plan (2019 Plan) adopted by Board of Directors.
2020-12-01	FDA 510(k) regulatory clearance for aprevo interbody implants for correction of adult lumbar spinal deformity.
2020-12-01	Series A convertible preferred stock issued.
2021-02-01	First U.S. patient implant using aprevo Technology Platform.
2021-04-30	Common Stock Warrant issued in connection with SVB Loan.
2021-05-01	Carlsbad, California office lease commenced.
2021-10-01	CMS awarded aprevo interbody implants NTAP (New Technology Add-on Payment) through October 2024.
2021-10-01	U.S. commercial launch of aprevo Technology Platform for lumbar spine fusion surgery.
2022-04-01	Series B convertible preferred stock issued.
2022-08-01	FDA cleared aprevo Technology Platform for treatment of patients with Degenerative Disc Disease (DDD) of the lumbar spine.
2022-12-01	Entered into loan and security agreement with Signature Bank (later Customers Bank).
2023-09-01	FDA granted second Breakthrough Device Designation for cervical technology.
2023-10-01	CMS adopted new MS-DRGs covering most lumbar spine fusion procedures involving custom-made anatomically designed interbody fusion devices.
2023-10-01	Drew $3.1 million under Customers Loan Agreement following revenue milestones.
2023-12-04	Carlsbad office lease modified, extending term to July 1, 2028.
2024-03-07	Third Amendment to Customers Loan Agreement, increasing credit facility to $18.8 million and issuing Series B Warrant.
2024-05-01	Drew $6.3 million under Customers Loan Agreement upon achievement of requisite revenue milestones.
2024-11-01	Received FDA 510(k) clearance for aprevo interbody implants for cervical interbody fusion surgeries.
2024-11-01	Launched Digital Production System (DPS) to deliver implants within 10 business days.
2024-12-24	William (Scott) Durall appointed Chief Commercial Officer.
2024-12-30	Fourth Amendment to Customers Loan Agreement, expanding credit facility to $27.5 million and issuing Series C Warrant.
2025-01-01	Issued 1,117,743 shares of Series C convertible preferred stock for $12.0 million.
2025-03-05	Granted Michael Cordonnier 112,478 performance and market-based vesting RSUs.
2025-04-01	CMS issued IPPS 2025 Proposed Rule including NTAP for qualifying aprevo cervical procedures.
2025-07-10	Effectuated a 1-for-5.58 reverse stock split.
2025-07-14	Successfully completed the first in-human personalized cervical procedure in the United States using the aprevo Technology Platform.
2026-01-01	Expected commercialization of the aprevo Technology Platform for cervical fusion surgery.
2027-01-01	Anticipated final data release for the COMPASS Registry.
2028-07-01	Carlsbad, California office lease expiration.
2029-10-31	Customers Loan Agreement maturity date.
2034-12-30	Series B and Series C Warrants expiration date.

Recommendation

hold

Carlsmed presents a compelling long-term investment thesis due to its innovative AI-enabled personalized spine surgery platform, strong revenue growth, and demonstrated clinical benefits compared to traditional methods. The company is addressing a large, established market with a significant unmet need and has secured favorable reimbursement pathways. However, the company is still in a high-growth, pre-profitability phase, incurring substantial net losses due to heavy investments in R&D and commercial expansion. Key risks include reliance on a single product, dependence on a limited number of CMOs, intense competition, and the inherent uncertainties of regulatory approvals and market adoption for new technologies. While the IPO provides a significant capital injection, the path to sustained profitability and market leadership is subject to successful execution of its growth strategies and effective management of operational and regulatory challenges. For a seasoned investor, a 'Hold' recommendation is appropriate, suggesting monitoring the company's progress in cervical market penetration, continued clinical evidence generation, and efficiency improvements in its supply chain before committing to a 'Buy' position.

Keywords

Spine Surgery, AI-Enabled Medical Technology, Personalized Implants, Lumbar Fusion, Cervical Fusion, Degenerative Disc Disease, Adult Spinal Deformity, Medical Devices, FDA Clearance, CMS Reimbursement, IPO, 3D Printing, Surgical Planning Software, Orthopedics, Healthcare Technology, Biomedical, Artificial Intelligence, Machine Learning, Patient-Specific Devices, S-1/A

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.